Printer Friendly

Completion of a non-exclusive discount agreement pursuant to A* 130a sgb v, section 8 for drug cimetidine.

Contract notice: Completion of a non-exclusive discount agreement pursuant to A* 130a sgb v, section 8 for drug cimetidine.

A* 130a SGB V, paragraph 8 provides health insurance and pharmaceutical companies, under discount agreements to include on statements to be to the detriment of public health insurance medicine. With regard to the relevant statutory provisions for public procurement, there is a regular process drug-related, rather than through the formal procedure DAK health. For by the tenderer in more detail in Appendix 2 to the contract calling for drugs to the above Drug (cimetidine - ATC A02BA01) intends to DAK health, however, pending the entry into force of new drugs enter discount agreements with all possible, at least to any interested pharmaceutical companies enter into appropriate contracts. The DAK health that this method based on the order value of less than EUR 200 000 to the lack of selection decision and therefore the non-discriminatory access capability for all pharmaceutical companies not within the scope of the cartel procurement law (Part 4 of the GWB A* 97 assumes ff .) falls. The notice published in the EU portal (ie in TED) is purely voluntary. A rebate agreement under the authorization model occurs for the first time on 1.11.2013 in force and shall expire on 31.10.2015. It ends automatically regardless of the entry into force of the exclusive contract to the above Drug resulted in a formal award procedure with one or more contractors. To the diversity of potential contractors to meet under the authorization model, each pharmaceutical company is allowed during the contract period to conclude a framework contract at any time and under the same conditions. The contract documents required for this purpose can be requested via the following email address: : Requirements for the degree, or the eventual accession to the entering into force on 1.11.2013 contracts is the full proof of sending the following / explanations / equipment (available on request from the above point of contact: to the contact person listed below the DAK health 1 Letter of Offer; : 2 Current proof of enrollment on the professional or trade register (not older than 6 months at dispatch) in accordance with the laws of the country where the company is based, for example, current trade register extract, copy is sufficient. : 3 Self-declaration of the company that none of the exclusion criteria according to A* 6 para 5 lit. a) to e) VOL / A is present. For this, the system is A1 to sign the application conditions, to provide the company stamp and file the original with the offer. : 4 Self-declaration by the fact that for those drugs for which the interested party wishes to conclude an agreement under that procedure, a regulatory drug approval, and

Tender documents : T18418365.html

2013 Al Bawaba (

Provided by an company
COPYRIGHT 2013 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Sep 26, 2013
Previous Article:Advice and support inbox / smartfix in the years 2014 and 2015.
Next Article:Completion of a non-exclusive discount agreement pursuant to A* 130a sgb v, section 8 for drug celiprolol.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters